# NAICS 62: Health Care & Social Assistance

## 524114 - Health Insurance (Cross-ref NAICS 52)

See `naics-52-finance.md` for full insurance profiles.

### Quick Reference
```
HEALTH INSURANCE MARKET:
├── UnitedHealth: $400B rev, 44.8M members, #1 in 44% metros
├── Elevance (Anthem): $175B rev, 46M members
├── Cigna: $230B rev (incl. Evernorth)
├── CVS/Aetna: $360B rev (integrated)
├── Humana: $112B rev (#2 Medicare Advantage)
└── HHI: 3,458 avg (97% markets "highly concentrated")
```

## 325412 - Pharmaceutical Manufacturing

### Big Pharma

```
PFIZER (PFE)
├── NAICS: 325412
├── Revenue: $58B (2024)
├── HQ: New York, NY
├── C-Suite:
│   ├── CEO: Albert Bourla (2019)
│   └── CFO: David Denton
├── Activist: Starboard Value ($1B+ stake)
├── Union: Limited
├── Key Drugs: Paxlovid, Ibrance, Eliquis
├── Patent Cliff: Multiple drugs expiring
└── Position: #1 US pharma by revenue

JOHNSON & JOHNSON (JNJ)
├── NAICS: 325412
├── Revenue: $85B (2024, pharma: $55B)
├── HQ: New Brunswick, NJ
├── CEO: Joaquin Duato (2022)
├── Activist: None
├── Spinoff: Kenvue (consumer, 2023)
├── Litigation: Talc ($8B+ settlement)
└── Position: #2 US pharma

MERCK (MRK)
├── NAICS: 325412
├── Revenue: $64B (2024)
├── HQ: Rahway, NJ
├── CEO: Rob Davis (2021)
├── Key Drug: Keytruda ($29.5B, 42% of rev)
├── Patent Cliff: Keytruda 2028
└── Position: #3 US pharma

ABBVIE (ABBV)
├── NAICS: 325412
├── Revenue: $56B (2024)
├── HQ: North Chicago, IL
├── CEO: Rob Michael (2024)
├── Key Drugs: Humira (declining), Skyrizi, Rinvoq
└── Position: #4 US pharma

ELI LILLY (LLY)
├── NAICS: 325412
├── Revenue: $45B (2024)
├── Market Cap: $750B+ (#1 pharma by value)
├── HQ: Indianapolis, IN
├── CEO: David Ricks (2017)
├── GLP-1 Drugs:
│   ├── Mounjaro: $11.5B (2024) → $18B (2025E)
│   └── Zepbound: $4.9B (2024) → $12.5B (2025E)
├── Market Share: ~57% GLP-1
└── Position: Highest-valued pharma globally

NOVO NORDISK (Denmark)
├── NAICS: 325412
├── Revenue: $37B (2024)
├── GLP-1 Drugs:
│   ├── Ozempic: $16.7B
│   └── Wegovy: $8.1B
└── Position: #2 GLP-1 market
```

## 424210 - Pharmaceutical Distribution

```
MCKESSON (MCK)
├── NAICS: 424210
├── Revenue: $309B (FY2024)
├── HQ: Irving, TX
├── C-Suite:
│   ├── CEO: Brian Tyler (2019)
│   └── CFO: Britt Vitalone
├── Market Share: ~35% drug distribution
├── Opioid Settlement: $8B+
└── Position: #1 drug distributor

CENCORA (COR, fka AmerisourceBergen)
├── NAICS: 424210
├── Revenue: $262B (FY2024)
├── HQ: Conshohocken, PA
├── CEO: Steve Collis
├── Market Share: ~33%
├── Opioid Settlement: $6.4B
└── Position: #2 drug distributor

CARDINAL HEALTH (CAH)
├── NAICS: 424210
├── Revenue: $227B (FY2024)
├── HQ: Dublin, OH
├── CEO: Jason Hollar
├── Market Share: ~32%
├── Opioid Settlement: $6.4B
└── Position: #3 drug distributor

BIG THREE DISTRIBUTION:
├── Combined Revenue: ~$776B
├── Combined Share: >90%
├── Opioid Settlements: $26B+ total
└── HHI: ~2,700+
```

## 622 - Hospitals

```
HCA HEALTHCARE (HCA)
├── NAICS: 622110
├── Revenue: $67B (2024)
├── Facilities: 180+ hospitals
├── HQ: Nashville, TN
├── CEO: Sam Hazen
├── Union: Limited (varies by state)
└── Position: #1 for-profit hospital operator

TENET HEALTHCARE (THC)
├── NAICS: 622110
├── Revenue: $21B (2024)
├── Facilities: 50+ hospitals
├── HQ: Dallas, TX
├── CEO: Saum Sutaria
└── Position: #2 for-profit hospitals

COMMUNITY HEALTH SYSTEMS (CYH)
├── NAICS: 622110
├── Revenue: $12B (2024)
├── HQ: Franklin, TN
├── Issues: High debt, divestitures
└── Position: #3 for-profit hospitals

NON-PROFIT SYSTEMS:
├── Kaiser Permanente: $100B+, 12M members (SEIU)
├── Ascension: $28B
├── CommonSpirit: $35B
├── Trinity Health: $21B
└── Providence: $27B
```

## 621 - Ambulatory Care

### Dialysis (Duopoly)

```
DAVITA (DVA)
├── NAICS: 621492
├── Revenue: $12.8B (2024)
├── Clinics: 2,700+
├── HQ: Denver, CO
├── CEO: Javier Rodriguez
├── Owner: Berkshire Hathaway (~40%)
├── Market Share: ~37%
└── Position: #1 US dialysis

FRESENIUS MEDICAL CARE (Germany)
├── NAICS: 621492
├── US Revenue: $14B
├── US Clinics: 2,400+
├── Market Share: ~38%
└── Position: #2 US dialysis

DIALYSIS DUOPOLY:
├── Combined Share: 75-80%
├── HHI: Highest in healthcare
└── FTC Investigation: 2024
```

## Sector Concentration

| Segment | Top 3 Share | HHI |
|---------|-------------|-----|
| Health Insurance | 60-70% | 3,458 |
| Drug Distribution | 90%+ | ~2,700 |
| PBM | 80% | ~2,400 |
| Dialysis | 80% | ~3,200 |
| For-profit Hospitals | 65% | ~1,600 |
